December 21, 2021 5:26pm
As I wrote this a.m., “Sector stock’s rise, stock’s fall – forget the sector and market, focus on the Christmas holiday coming”
Pre-open indication results: 6 HITs, 1 MISS
The Biostage (BSTG) Chronicles: closed down-$0.49 with 4,582 shares traded to $2.48 after Monday’s +$0.53 with 425 shares traded. Has he, David Green, the new interim CEO and chairman CONDONED the “pump and promote”?
If I have learned one thing as a former research analyst, venture and public markets investor to a journalist; it is that your life and your bank account are largely tied to your questioning of price movements and targets.
Who else is tracking a broad representative of cell and gene therapy equities – with facts supported by real numbers?
The Dow closed UP +560.54 points (+1.60%); the S&P closed UP +81.21 points (+1.78%) while the Nasdaq closed UP +360.14 points (+2.40%)
Indexes rebounded sharply on Tuesday following three days of losses amid fears about the fast-spreading Covid omicron variant.
The sector appears to be reacting to a short-term oversold position.
A relevant quote, “As we head into the shortened holiday week amid surging omicron cases, continued supply chain pressures and the failure of the Build Back Better plan, increased volatility and thinner trading volumes could cause the market to overreact, which could be a buying opportunity in the run-up to Christmas,” said Mark Hackett, Nationwide’s chief of investment research.
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …
- Tuesday opened positive at 25 up/6 downs, 3 flats and 1 acquired, flipped negative at the mid-day at 13/19, 2 flats and 1 acquired, ending with a positive close of 20/9, 5 flats, and 1 acquired;
- Monday opened negative at 1 up/32 downs, 2 flat and 1 acquired, flipped positive at the mid-day at 18/15, 1 flat and 1 acquired, ending with a neutral close of 16/16, 2 flats, and 1 acquired;
RegMed Investors’ (RMi) pre-open: “the roller-coaster increases volatility with thinner trading volumes. Sector stock’s rise, stock’s fall – forget the market, focus on the Christmas holiday coming” … https://www.regmedinvestors.com/articles/12235
Pre-open indication results: 6 HITs: < Biostage (OTCQB: BSTG -$0.49); SELL into Strength: Alnylam Pharmaceuticals (ALNY +$1.30), Ultragenyx (RARE +$0.36), BioLife Solutions (BLFS +$1.53), CRISPR Therapeutics (CRSP -$1.13), Intellia Therapeutics (NTLA +$2.54)> and 1 MISS: < Editas Medicine (EDIT -$0.38)>
Key Metric - volume
Sector volume INCREASED with 7 of the 20-upside having higher than the 3-month average volume with INCREASED volume of 5 of 9-downside having higher than the 3-month average volume;
Note: Biostage (BSTG) closed down-$0.49 with 4,582 shares traded to $2.48 after Monday’s +$0.53 with 425 shares traded after Friday’s down -$0.37 on Friday with 5,734 shares traded, Thursday’s flat with 371 shares traded after Wednesday’s flat with 3,281 shares traded, Tuesday’s flat with 500 shares traded and Monday’s 0 shares traded. Has he, David Green, the new interim CEO and chairman CONDONED the “pump and promote”?
Jumping with share pricing momentum (10 of 20):
- Fate Therapeutics (FATE +$3.18 after Monday’s +$1.36),
- Intellia Therapeutics (NTLA +$2.54 after Monday’s -$5.59),
- ReNeuron (RENE.L +$2.50 after Monday’s $0.00)
- Vericel (VCEL +$2.55 after Monday’s -$2.52),
- BioLife Solutions (BLFS +$1.53 after Monday’s +$0.17),
- Alnylam Pharmaceuticals (ALNY +$1.30 after Monday’s +$3.72),
- Regenxbio (RGNX +$1.16 after Monday’s +$0.46),
- bluebird bio (BLUE +$0.87 after Monday’s -$0.09),
- Chinook Therapeutics (KDNY +$0.55 after Monday’s -$0.10),
- Ionis Pharmaceuticals (IONS +$0.42 after Monday’s -$0.25)
Hammered in today’s market (9 of 9):
- CRISPR Therapeutics (CRSP -$1.13 after Monday’s -$1.68),
- Biostage (BSTG -$0.49 after Monday’s +$0.529),
- Editas Medicine (EDIT -$0.38 after Monday’s +$0.32),
- Cellectis SA (CLLS -$0.36 after Monday’s -$0.30),
- uniQure NV (QURE -$0.19 after Monday’s +$0.63),
- Sage Therapeutics (SAGE -$0.28 after Monday’s -$0.20),
- Global Blood Therapeutics (GBT -$0.12 after Monday’s +$0.71),
- Bellicum Pharmaceuticals (BLCM -$0.02),
- Athersys (ATHX -$0.019)
- 5 – Precigen (PGEN), Applied Genetic Technologies (AGTC), Homology Medicine (FIXX), Mesoblast (MESO), Verastem (VSTM) and 1- Stemline Therapeutics (STML) – acquired
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Tuesday, the IBB closed up +0.61% and XBI closed up +0.68%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Tuesday was down -1.86 points or -8.13% at 21.01
December, the second month of Q4/21:
Tuesday closed positive with 20 incliner, 9 decliners, 5 flat and 1 acquired
Monday (12/20) closed neutral with 16 incliner, 16 decliners, 2 flats and 1 acquired
The BOTTOM LINE: An oversold bounce … after a neutral sector close on Monday.
Monday’s sector movers were: Alnylam Pharmaceuticals (ALNY) as went – Friday, Ultragenyx (RARE), Global Blood Therapeutics (GBT) and again Fate Therapeutics (FATE) as went Friday
Friday’s trading action was marked by jumps in share pricing by Intellia therapeutics (NTLA), CRISPR Therapeutics (CRSP) which Monday were hammered, ReNeuron (RENE.L -$1.00) and was flat on Monday, Mesoblast (MESO -$0.23) – up on Monday +$0.10 and Bellicum Pharmaceuticals (BLCM -$0.012) - up on Monday +$0.09; Friday Athersys (ATHX) dived then, gained +$0.01 on Monday along with Caladrius Biosciences (CLBS) which also gained on Monday +$0.025 – which had barely hung in the Nasdaq on Friday.
Despite gains and losses for the sector last week, direction is still unclear as Monday the sector closed neutral and Tuesday closed positive.
Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.